Abstract

Alvotech will report fourth-quarter 2025 results on March 18, 2026 Post Market; this preview distills the latest reported figures, forecasts, and recent media coverage to frame expectations for revenue, profitability, and earnings, while highlighting where the market is focused ahead of the print.

Market Forecast

Based on the latest available estimates, Alvotech’s current-quarter revenue is projected at 164.93 million USD, implying 43.01% year-over-year growth, with estimated EPS at -0.05 (an 88.33% year-over-year improvement) and estimated EBIT at 38.33 million USD (up 61.60% year-over-year). Forecasts for gross profit margin and net profit margin were not specified, and are therefore omitted.

The company’s commercial engine is expected to remain anchored in its product sales, with momentum supported by recent regulatory milestones and launch progress in multiple regions. Within the portfolio, the licensing and other revenue line appears positioned for incremental contributions from milestones and partner-related activities; last quarter it totaled 101.27 million USD.

Last Quarter Review

In the prior quarter, Alvotech delivered revenue of 113.86 million USD (up 10.56% year-over-year), a gross profit margin of 69.26%, a GAAP net loss attributable to the parent company of -5.25 million USD translating to a net profit margin of -4.61%, and adjusted EPS of -0.05 (down 150.00% year-over-year).

A key highlight was gross margin resilience at 69.26%, reflecting favorable product economics even as scaling and mix effects weighed on the bottom line. In terms of composition, product revenue was 204.73 million USD and licensing and other revenue was 101.27 million USD in the last reported period; year-over-year segment growth rates were not disclosed.

Current Quarter Outlook

Main business: Product sales and launch execution

The core focus this quarter is execution in product sales as launches deepen and distribution expands with partners. The recent six-month news window featured a cluster of regulatory milestones that can enable broader market access. On September 23, 2025, commercial partners secured approvals in Japan for three products and positive opinions in Europe for two, which together point to potential step-ups in demand as launches advance in those geographies and beyond. The impact in the current quarter will depend on the pace of partner rollout, initial stocking patterns, and early prescription uptake, which tend to be staggered across channels and territories.

Revenue quality within the product line is central to sustaining gross margin near the strong prior-quarter level of 69.26%. Partner economics, price realization in early-stage markets, and the mix between direct sales and partner-sourced volumes can all influence unit profitability. If early wins skew toward products with relatively higher contribution margins, headline margin could hold firm despite scale-up costs; if launch support and channel investments are more front-loaded, gross margin could moderate in the near term even as revenue expands. The market will be sensitized to how these puts and takes flow into the EBIT bridge, given the forecast calls for EBIT growth of 61.60% year-over-year to 38.33 million USD while revenue is projected to rise by 43.01%.

Considering the sequential dynamics, sell-through velocity after initial shipments matters as much as top-line booking. Any timing effects between partner orders and end-market consumption could introduce volatility quarter to quarter. That means investors are likely to parse commentary on reorder cadence, geographic breadth of adoption, and the balance between volume growth and pricing as key indicators of the durability of the projected revenue ramp.

Most promising business: Licensing and other revenues

Licensing and other revenue was 101.27 million USD in the last reported period and remains a potential swing factor this quarter given the milestone-based nature of partner agreements. Regulatory determinations and launch progress can trigger payments that are typically recognized upon achieving clearly defined events, which can create meaningful quarter-to-quarter variability. The September 23, 2025 update that partners obtained approvals in Japan for multiple products and positive opinions in Europe for two candidates raises the probability of milestone flows in adjacent periods as approvals convert to commercial starts and as contractual conditions are met.

This revenue stream generally carries a higher margin profile compared with certain early commercialization activities, so a higher mix of licensing inflows tends to support both gross margin and operating margin. The interplay between such milestones and core product sales will likely influence the path of EPS in the quarter. Given the forecast EPS estimate of -0.05 with an 88.33% year-over-year improvement, even modest licensing over-delivery could have an outsized effect on the bottom line relative to expectations, while timing slippage could produce the opposite effect.

Visibility into exact milestone timing is inherently limited from the outside, which is why management’s narrative around pending partner events, launch timing, and potential regulatory clearances will be crucial for triangulating the likelihood of recognition in this quarter versus subsequent periods. Observers will pay close attention to any updates tied to conversion of prior positive scientific opinions into formal approvals and the commencement of partner-led commercial activity.

Stock-price drivers this quarter: Revenue trajectory, margin cadence, and regulatory catalysts

Market focus will circle around whether Alvotech can meet or exceed the revenue projection of 164.93 million USD and demonstrate an earnings trajectory consistent with the estimated EPS of -0.05. The topline mix between product sales and licensing can materially influence gross margin and operating leverage. If product volumes ramp faster than anticipated and licensing events land as expected, the company could deliver a stronger EBIT flow-through than modeled, supporting the 61.60% year-over-year EBIT growth outlook. Conversely, if launch curves are slower or milestone recognition shifts later, reported results might fall nearer the low end of the revenue and earnings ranges implied by the estimates.

Margin cadence will be another determinant of share-price reaction. A repeat of last quarter’s gross margin at 69.26% would likely be interpreted as evidence of healthy economics in the current mix, whereas material compression could prompt questions about cost absorption, channel support, or the relative contribution of early-stage launches versus steady-state products. Investors will also consider whether the net margin directionally narrows from the last quarter’s -4.61%, in line with the anticipated EPS improvement implied by the forecast.

Lastly, regulatory and corporate milestones in the period can act as contemporaneous catalysts. Recent filings in January and February 2026 indicate an active corporate update cadence that could intersect with partner initiatives, though details were not specified in the public notices. Any confirmation of approvals, launches, or partner milestones around or shortly after the financial report date could alter expectations for the subsequent quarter and potentially overshadow in-quarter variances. The company’s update on cash discipline relative to the trajectory of EPS and EBIT will also shape sentiment, given the importance of financing flexibility during periods of rapid scale-up.

Analyst Opinions

Across the available commentaries during the six-month window ending March 11, 2026, the tone skewed bullish, with supportive views outweighing bearish ones by a margin of 100% to 0%. The market narrative has emphasized the company’s visible revenue acceleration—consensus points to 164.93 million USD this quarter, up 43.01% year-over-year—alongside a projected improvement in EPS to -0.05, reflecting an 88.33% year-over-year change. Coverage has highlighted recent regulatory milestones and the potential for partner-driven launches to translate into both top-line growth and incremental licensing flows, which together underpin the majority’s constructive stance.

Notably, commentary since September 23, 2025 has underscored the significance of multiple approvals in Japan and favorable scientific opinions in Europe for two products, reinforcing expectations for broader commercial availability and revenue capture through partners. In the days leading up to March 18, 2026, observers have also pointed to the company’s communication on March 04, 2026 regarding the timing of the results as a signpost that a more complete operational update is imminent, with specific attention on the mix between product sales momentum and the cadence of milestone recognition.

The dominant view anticipates that execution on launches and partner contributions can support the forecasted EBIT growth of 61.60% year-over-year to 38.33 million USD. Proponents expect the revenue mix to be favorable enough to defend gross margin near recent levels, while acknowledging that quarter-to-quarter variability may arise from timing of milestone revenue and early-stage commercialization costs. The bullish camp therefore frames this quarter as a validation point for the multi-pronged revenue model: product sales as the recurring base and licensing as an episodic enhancer. Should the company match or surpass the revenue and EPS targets while signaling sustained momentum from recent approvals, these commentators believe the setup could remain supportive into the next reporting cycle.